Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMA ADC Extension in mCRPC
NCT02020135Phase 2Completed
- Sponsor
- Progenics Pharmaceuticals
- Start
- Oct 2013
- Primary completion
- Feb 2015
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of psma adc in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Progenics Pharmaceuticals. Started Oct 2013; status: completed.
02
Drugs
psma adc
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02020135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02020135.